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Advanced glycation end products (AGE) have been demonstrated to induce the osteogenic trans-
differentiation of vascular smooth muscle cells (VSMC). Strontium ranelate (SR) is an anti-osteoporotic
agent that has both anti-catabolic and anabolic actions on bone tissue. However, in the last years SR
has been associated with an increase of cardiovascular risk. We hypothesize that SR can increase the
osteoblastic trans-differentiation of VSMC and the induction of extracellular calcifications, an effect that
could be potentiated in the presence of AGE and inhibited by simultaneous administration of vitamin D.
The present results of our in vitro experiments demonstrate that AGE and SR alone or in combination,
stimulate L-type calcium channels, causing an increase in reactive oxygen species and activation of both
ERK and NFkB, with the final effect of promoting the osteogenic shift of VSMC. Importantly, these in vitro
effects of AGE and/or SR can be prevented by co-incubation with vitamin D.
© 2017 Elsevier B.V. All rights reserved.1. Introduction
Osteoporosis is a highly prevalent condition, closely related to
the aging process. The most common treatments for osteoporosis
include oral supplementation with calcium and vitamin D, and/or
anti-osteoporotic drugs such as bisphosphonates, strontium rane-
late (SR) or intermittent administration of rhPTH. In particular, SR is
an interesting therapeutic option since it shows dual in vitro and
in vivo anti-osteoporotic action: it decreases osteoclastic bone
resorption while stimulating osteoblastic bone formation (Marie
et al., 2011).
In order to select the best treatment option for an individual
patient, it is important to investigate possible non-skeletal actions
of these drugs or of their possible therapeutic combinations. For
example, calcium supplementation on its own in patients with a
negative balance of this cation (such as older adults) is controver-
sial: several studies have found it to increase cardiovascular risk,
although others have not (Bostick et al., 1999; Foley et al., 2008; Isoedlinsky).
h.et al., 1999). On the other hand, low serum levels of vitamin D that
are prevalent in older adults have been associated with an increase
both in cardiovascular risk, and in postural instability (and thus of
bone fractures) (Body et al., 2012).
Osteoporosis as well as cardiovascular disease and diabetes may
share some common pathophysiological mechanisms of disease
such as the effects of accumulated advanced glycation end products
(AGE) and the increase of intracellular oxidative stress that takes
place after AGE interaction with its cognate receptor RAGE (Yan
et al., 1994; McCarthy et al., 2013; Schmidt et al., 1994). We have
previously demonstrated that AGE can induce a decrease in oste-
oblastic proliferation, differentiation and survival, and that these
potentially deleterious effects for bone are prevented by SR
(Fernandez et al., 2013). Regarding cardiovascular disease, AGE has
been demonstrated to increase the proliferation and migration as
well as osteogenic trans-differentiation of vascular smooth muscle
cells (VSMC) following AGE-RAGE interaction (Suga et al., 2011; Ma
et al., 2015). Thus, the effects of AGE on events leading to extra-
cellular matrix calcification appear to be cell-type specific: anti-
osteogenic in the case of pre-osteoblasts, but pro-osteogenic for
VSMC. Following this line of reasoning, the modulation by stron-
tium of AGE-induced effects on mineralization could also be
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the opposite for VSMC). Interestingly, it was demonstrated that
physiological concentrations of vitamin D induce protective effects
on vascular calcifications, whereas vitamin D deficiency is associ-
ated with an increase in vascular calcifications (McCarty and
DiNicolantonio, 2014; Zimmermann et al., 2011).
Recently, SR has been claimed to increase cardiovascular risk,
peripheral arterial disease, non-fatal myocardial infarction and
venous thromboembolism, and its use was restricted by the Euro-
pean Medicine Agency (EMA 2013). Nevertheless, other commu-
nications have shown conflicting data regarding this issue.
Svanstr€om and coworkers showed in a nationwide cohort study of
postmenopausal women in Denmark, using as a primary outcome
acute coronary syndrome and as a secondary outcome any-cause
mortality, that compared to the use of alendronate or risedronate,
strontium ranelate was not associated with an increased risk of
both end-points (Svanstrom et al., 2014). Another study by Cooper
and coworkers using myocardial infarction, hospitalization with
myocardial infarction, or cardiovascular death as primary outcome,
was unable to find evidence for a higher risk for cardiac events
associated with the use of strontium ranelate in postmenopausal
osteoporosis (Cooper et al., 2014).
Since the actions of strontium may have similarities to those of
extracellular calcium, we propose the following working hypoth-
esis: strontium ranelate could increase the osteoblastic trans-
differentiation of VSMC and thus the induction of extracellular
calcifications, an effect that could be potentiated in the presence of
AGE and inhibited by simultaneous coincubation with vitamin D.
The aim of this study was to evaluate the in vitro effects of stron-
tium ranelate on VSMC number, migration and transdifferentiation
to the osteoblastic phenotype, with or without the influence of
AGE, and to determine if vitamin D is able to modulate strontium
ranelate and/or AGE effects on VSMC.
2. Materials and methods
2.1. Preparation of advanced glycation end products
Advanced glycation end product-modified bovine serum albu-
min (AGE) was prepared by incubation of 10 mg/ml bovine serum
albumin (Sigma, Argentina) with 33 mM d-glycolaldehyde in
150 mM phosphate-buffered saline pH 7.4 at 37 C for 3 days under
sterile conditions after which unincorporated sugar was removed
(Gangoiti et al., 2008). Control bovine serum albumin (BSA) was
incubated in the same conditions without sugar. The formation of
AGE was assessed with a Shimadzu spectrofluorometer by their
characteristic fluorescence - emission maximum at 420 nm upon
excitation at 340 nm. The estimated level of AGE obtained by this
in vitro incubation was 18.5% relative fluorescence units/mg pro-
tein, in contrast to 3.2% for control BSA.
2.2. Isolation and incubation of vascular smooth muscle cells
(VSMC)
Adult male SpragueeDawley rats (190e210 g) weremaintained
in a temperature - controlled room at 23 C, with a fixed 12 h light:
12 h darkness cycle, and fed standard rat laboratory chow and
water ad libitum. All experiments with animals were performed in
conformity with the Guidelines on Handling and Training of Lab-
oratory Animals published by the Universities Federation for Ani-
malsWelfare (Guide of TCaUoLA, 2011). Approval for animal studies
was obtained from the institutional animal care committee (CICUAL
approval number: 001-05-15). Animals were sacrificed by cervical
dislocation under anesthesia and aortas were dissected.
VSMC were isolated from aorta rings as previously described(Rodriguez et al., 2006). Briefly, tunica adventitia was dissected and
the aorta cut into 1 mm rings. Individual rings were cultured in
25 cm2 flasks at 37 C in a humidified incubator with an atmo-
sphere of 95% air-5% CO2. Tissue explants were further cultured in
DMEM containing 10% fetal bovine serum (FBS) (Natocor, Cordoba,
Argentina) and antibiotic-antimycotic products (10,000 U/ml
penicillin G sodium, 10,000 mg/ml streptomycin sulfate, and 25 mg/
ml amphotericin B in 0.85% saline). The medium was changed
initially after 24 h and then every 2e3 d. After about 2e3 weeks,
when cells had formed a confluent monolayer, they were harvested
by addition of 0.05% trypsin, and the culture was continued using
DMEM containing 10% FBS. VSMCwere characterized by expression
of a-actin.
For the different experiments, cells were seeded on multi-well
plates and incubated in DMEM and 100 mg/ml of either BSA or
AGE, with or without 0.1 mM of strontium ranelate (SR, kindly
provided by Institut de Recherches Internationales Servier). Alter-
natively, cells were cultured in absence or presence of 50 ng/ml of
cholecalciferol (Vit D), 2.5 ng/ml calcitriol (1,25 Vit D), 10 mM
Nifedipine, Vitamins E and C (50 mM of each), 100 mM of Sulfasa-
lazine or 0.5 mM of PD98059.
2.3. Cell number studies
A mitogenic bioassay was carried out as previously described
(Okajima et al., 1992) with modifications. Briefly, VSMC were
cultured in 24-well plates for 24 or 48 h submitted to different
experimental conditions, after which they were washed with
phosphate buffered saline (PBS) and fixed with 5% glutaraldehyde/
PBS for 10 min. Cells were stained with 0.5% crystal violet (25%
methanol) for 10 min. Excess dye was discarded and the plate was
extensively washed with water. The dye taken up by cells was
extracted using 0.5 ml/well 0.1 M glycine/HCl buffer, pH 3.0/30%
methanol, which was transferred to test tubes and its absorbance
read at 540 nm. Correlation between the cell number and the
absorbance at 540 nm has been previously established (Salice et al.,
1999).
2.4. Cell migration
VSMC migration was assessed by an in vitro wound assay as
previously described (Molinuevo et al., 2008). Confluent mono-
layers of VSMC were scratched (wounded) with a pipette tip. After
washing with culture media, cells were incubated for an additional
12 h in DMEMd10% FBS with either BSA or AGE, in the presence or
absence of SR. After this incubation period, the monolayers were
fixed and stained with Giemsa. Cell migration distance from the
edge of the wound was assessed using the freeware Image J pro-
gram (www.macbiophotonics.ca/imagej).
2.5. Osteogenic differentiation
Osteogenic induction of VSMC was performed by incubating
confluent cell monolayers in DMEM-10% FBS supplemented with
5 mM b-glycerolphosphate and 25 mg/ml ascorbic acid. Under these
culture conditions cells begin to secrete type 1 collagen, express
alkaline phosphatase activity (ALP) and accumulate extracellular
mineral deposits after 1 week, reaching a maximum after 2 weeks.
For ALP determination, cells werewashedwith phosphate-buffered
saline (PBS) and solubilized in 0.5 ml 0.1% Triton -100. Aliquots of
this total cell extract were used for protein determination
(Bradford, 1976) and for measurement of ALP by spectrophoto-
metric determination of initial rates of hydrolysis of p-nitrophenyl-
phosphate (p-NPP) to p-nitrophenol (p-NP) at 37 C for 10 min. For
evaluation of type 1 collagen production, cells were fixed with
Fig. 1. Effect of AGE and/or SR on VSMC. (A) There is a significative increase on VSMC
number caused by AGE or SR, while the co-incubation showed an additive stimulatory
effect on cell proliferation. (B) AGE or SR promotes VSMC migration, with an additive
effect in the co-incubation. Results are expressed as the mean ± SEM, n ¼ 8. #: p < 0.05
vs. BSA; ##: p < 0.01 vs. BSA; ###: p < 0.001 vs. BSA; **: p < 0.01 vs. AGE; ff: p < 0.01
vs. BSA þ SR.
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material was dissolved in 1 ml 0.1 N sodium hydroxide and the
absorbance of the solution was recorded at 550 nm (Fernandez
et al., 2011). Accumulation of extracellular mineral deposits was
evaluated by staining with Alizarin S Red, and quantitated spec-
trophotometrically at 540 nm after solubilizationwith 0.1 N sodium
hydroxide (Fernandez et al., 2011).
2.6. Western blot assays
Cell monolayers were lysed with Laemmli's buffer (Laemmli,
1970). Total protein content of the cell lysates was evaluated by a
micro-method (Lowry et al., 1951). Lysates were heated to 100 C
for 3 min, after which aliquots containing 40 mg of protein were
subjected to 10% sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis. The separated proteins were then transferred to PVDF
membranes (Millipore, Bedford, MD), which were blocked in 3%
non-fat dry milk in Tris-buffered saline (TBS) for 2 h at room
temperature. They were then incubated at 4 C for 24 h with anti-
Runx2(Santa Cruz Biotechnologies, sc-10758, Lot #H1909), anti-a-
actin (Santa Cruz Biotechnologies, sc-53142, Lot #H1909), or anti-b-
actin polyclonal antibodies (Novus Biologicals, NB600-503, Lot #
A5) diluted 1:2000 in PBS with 0.5% bovine serum albumin. After
four washes in PBS with 0.1% Tween 20, the membranes were
incubated with a secondary goat anti-rabbit antibody, followed by
staining with the peroxidase-biotin reagent and diaminobenzidine
from the Vectastain kit. The intensity of the Runx2, a-actin and b-
actin specific bands was quantified by densitometry after scanning
the PVDF membrane with a Hewlett-Packard Scanjet 4C. Images
were analysed using the gel plugin of Image J program (www.
macbiophotonics.ca/imagej).
2.7. Reactive oxygen species
Stock solutions of dihydrorhodamine (DHR) (25 mM) and
rhodamine123 (0.5 mM) were prepared in nitrogen-purged dime-
thylformamide and stored in the dark at 20 C until used (Cortizo
et al., 2000). A fresh 10mM solution of DHR in DMEMwas prepared
every day. VSMCwere incubated with AGEs, BSA and/or SR for 12 h,
after which the culture media was replaced by DHR in DMEM and
cells were additionally incubated for an additional 4 h at 37 C.
VSMC monolayers were then washed twice with PBS and lysed
with 1 ml of 0.1% Triton 100. In the lysate, fluorescence intensity
of the oxidized product rhodamine was determined (excitation
wavelength, 495 nm; emission wavelength, 532 nm), using an
Shimadzu RF-1500 spectrofluorometer. Fluorescence intensity was
corrected for protein content (Bradford, 1976). A standard curve of
rhodamine123 was constructed from 0.1 to 5 mM.
2.8. Statistical analysis
Three independent experiments were run for each experimental
condition. Results are expressed as the mean ± SEM. One Way
ANOVA with Dunnett's post test was performed using GraphPad
InStat version 3.05 GraphPad Software, San Diego, California USA.
P < 0.05 was considered to be statistically significant.
3. Results
3.1. Effects of AGE and/or SR treatment on VSMC number and
migration
In a first series of experiments we evaluated the effect of 100 mg/
ml AGE or BSA and/or 0.1 mM SR on VSMC number. We found a
significant increase in cell number after 48 h of AGE treatment(Fig. 1A). On its own, SR also significantly increased VSMC number
compared to BSA. Co-incubation of SR and AGE induced an additive
increase in VSMC number (Fig. 1A). This increase in VSMC number
caused by AGE and/or SR was completely prevented by treatment
with either 10 mM nifedipine (L-type calcium channel inhibitor), a
mixture of vitamins C and E, oxidative stress inhibitors (50 mM of
each), 100 mM sulfasalazine (IKKS inhibitor, that prevents NFkB
nuclear translocation), 50 ng/ml of vitamin D or 0.5 mM PD 98,059
(a ERK kinase inhibitor) (Fig. 2AeE).
The migration ability of VSMC was evaluated using the scratch
wound assay. We found that either AGE or SR significantly
increased VSMC migration compared to BSA (Fig. 1B), and that co-
incubation of AGE with SR induced an additive effect. Again, the
effect of both AGE and SR alone or in combination could be pre-
vented by co-treatment with either nifedipine, a mixture of vita-
mins E and C, sulfasalazine or vitamin D (Fig. 3AeD).
Fig. 2. Effect of 10 mM nifedipine (A), 50 mM vitamin E and C (B), 100 mM sulfasalazine (C), 50 ng/ml Vit D (D) or 0.5 mM PD 98,059 (E) on cells number. Results are expressed as the
mean ± SEM, n ¼ 8. #: p < 0.05 vs. BSA; ##: p < 0.01 vs. BSA; ###: p < 0.001 vs. BSA; **: p < 0.01 vs. AGE; ff: p < 0.01 vs. BSA þ SR.
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In additional experiments, we evaluated the effect of AGE and/or
SR on the osteoblastic trans-differentiation of VSMC. We found thatthe addition of AGE to the osteogenic media caused an increase in
collagen type I production (Fig. 4A), alkaline phosphatase activity
(Fig. 4B) and extracellular mineral deposits (Fig. 4C) while it
increased the expression of the osteogenic transcription factor
Fig. 3. Effect of 10 mM nifedipine (A), 50 mM vitamin E and C (B), 100 mM sulfasalazine (C) or 50 ng/ml Vit D (D) on VSMC migration. Cell migrationwas evaluated by the wound assay
assessing the cell-free area after 12 h. Results are expressed as the mean ± SEM, n ¼ 8. #: p < 0.05 vs BSA; ##: p < 0.01 vs. BSA; ###: p < 0.001 vs. BSA; **: p < 0.01 vs. AGE; ff:
p < 0.01 vs. BSA þ SR.
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VSMC phenotype (Fig. 5B). Similarly, SR on its own also caused
VSMC to increase their production of collagen and extracellular
mineral deposits, to stimulate alkaline phosphatase activity (Fig. 4)
and to increase Runx2 expression while decreasing a-actin
expression (Fig. 5). SR co-incubated with AGE caused an additive
effect on the induction of osteogenic parameters and in the
decrease of VSMC phenotypic markers (Figs. 4 and 5). Pro-
osteogenic effects induced by AGE and/or SR, evaluated by the
type 1 collagen secretion, could be prevented by co-incubationwith
either nifedipine, a mixture of vitamins E and C, sulfasalazine or
PD98059 (Fig. 6AeD). Similar preventive effects of AGE and/or SR
pro-osteogenic action were observed both for vitamin D (chole-
calciferol) and for 1,25(OH)2-vitamin D (calcitriol) (Fig. 6E). In
addition, vitamin D also prevented the stimulation of Runx2
expression (Fig. 6F) and extracellular mineral deposits induced by
AGE and/or SR (Fig. 6G).
3.3. Role of intracellular oxidative stress on the osteogenic actions
of AGE and/or SR
In order to investigate the role of oxidative stress on the actions
of AGE, SR or their combination, we measured their effect on pro-
duction by VSMC of intracellular reactive oxygen species (ROS). Wefound that 100 mg/ml of AGE caused a significant increase in ROS
production compared to BSA (Fig. 7A). SR also increased ROS pro-
duction, while co-incubation of SR with AGE induced an additive
effect (Fig. 7A). Nifedipine, vitamin D or a mixture of vitamins C and
E completely prevented the increase in ROS production induced by
AGE and/or SR (Fig. 7BeD). Similar preventive effects were
observed for calcitriol (data not shown). On the other hand, co-
incubation with sulfasalazine did not prevent AGE and/or SR-
induced ROS production (Fig. 7E).
4. Discussion
In the present work we evaluated the osteogenic trans-
differentiation of VSMC after co-incubation with BSA or AGE and/
or SR, and its possible modulation with vitamin D. One of the first
steps for transition from myocytic to osteogenic phenotype is an
increase in cellular secretory, proliferative and migratory capacity
(Owens et al., 2004). In our experiments with VSMC, we found an
AGE-induced increase in cell number and migration (compared to
BSA). On the other hand, other authors described that AGEs can also
induce apoptosis on VSMC involving oxidative stress mechanisms
(Koike et al., 2016). Additionally, and in agreement with the pre-
vious research of other authors, we found an AGE-induced increase
in the expression of osteogenic phenotype markers (alkaline
Fig. 4. Effect of AGE and/or SR on osteogenic differentiation of VSMC. Osteoblastic
differentiation was evaluated as collagen type 1 expression (A), alkaline phosphatase
activity (B) and calcium nodules (mineral, C). Results are expressed as the mean ± SEM,
n ¼ 8. #: p < 0.05 vs. BSA; ##: p < 0.01 vs. BSA; ###: p < 0.001 vs. BSA; *: p < 0.05 vs.
AGE; **: p < 0.01 vs. AGE; f: p < 0.05 vs. BSA þ SR.
Fig. 5. Effect of AGE and/or SR on the expression of the osteogenic marker Runx2 (A)
and the miogenic marker a-actin (B). Western blot lanes: 1-BSA, 2-AGE, 3-BSA þ SR, 4-
AGE þ SR. Results are expressed as the mean ± SEM, n ¼ 8. #: p < 0.05 vs. BSA; ##:
p < 0.01 vs. BSA; *: p < 0.05 vs. AGE; f: p < 0.05 vs. BSA þ SR.
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formation, Runx2/b-actin ratio) (Ren et al., 2009; Tanikawa et al.,
2009; Wang et al., 2003). Although those authors described pro-
Fig. 6. Effect of 10 mM nifedipine (A), 50 mM vitamin E and C (B), 100 mM sulfasalazine (C), 0.5 mM PD98059 (D) or 50 ng/ml Vit D and 2.5 ng/ml 1,25Vit D (E) on collagen type 1
expression. The effect of cholecalciferol on Runx2 expression (F) and mineral production (G) was also evaluated. Western blot lanes: 1- BSA, 2- BSA þVitD, 3- AGE, 4- AGE þ VitD, 5-
BSA þ SR, 6- BSA þVitD þ SR, 7- AGE þ SR, 8- AGE þ VitD þ SR. Results are expressed as the mean ± SEM, n ¼ 8. #: p < 0.05 vs. BSA; ##: p < 0.01 vs. BSA; ###: p < 0.001 vs. BSA; **:
p < 0.01 vs. AGE; f: p < 0.05 vs. BSA þ SR; dd: p < 0.01vs. AGE þ SR.
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Fig. 6. (continued).
Author's Personal Copyosteogenic actions of AGE on VSMC, none evaluated the decrease of
a-actin as a marker of smooth muscle phenotype. In our present
work, we demonstrate that exposure of VSMC to AGE induces loss
of a-actin and acquisition of osteoblastic genes. Other authors
previously demonstrated that VSMC lose their myocytic phenotype
as they trans-differentiate to osteoblasts (Steitz et al., 2001). In
particular they showed that induction of vascular calcifications was
concomitant with loss of smooth muscle a-actin and smooth
muscle 22alpha expression, and with gain of osteopontin expres-
sion both in vitro and in vivo. On the other hand, we have previ-
ously demonstrated that extracellular matrix mineralization is
impaired in vitro and in vivo in the presence of AGE, as well as in
pathological conditions where AGE accumulates such as diabetes or
the metabolic syndrome (Cortizo et al., 2003; Felice et al., 2012;
McCarthy et al., 1997, 1999, 2001a,b; Mercer et al., 2004; Tolosa
et al., 2013). These apparently opposing effects of AGE (anti-oste-
ogenic for bone cells, pro-osteogenic for VSMC), are in fact sup-
ported by several population studies that point out the coexistence
of bone loss with calcifications of the aortic tunica media. Although
the molecular mechanisms that regulate this phenomenon are
incompletely known, it has been suggested that AGE plays an
important role in this process (Campos-Obando et al., 2015; Kiel
et al., 2001). Previous studies have demonstrated that both in
VSMC and in osteoblasts AGE interact with its receptor RAGEwhich
in turns activates intracellular signals that activate pro-
inflammatory genes responsible of its effects on these cells (Suga
et al., 2011; McCarty and DiNicolantonio, 2014; Cortizo et al.,
2003;McCarthy et al., 1999;Mercer et al., 2004;Menini et al., 2013).
Strontium ranelate (SR) has been approved for treatment of
postmenopausal osteoporosis. However, in 2014 the European
Medicine Agency (EMA) restricted the use of SR because its concern
about associated cardiovascular risk (peripheral thrombosis, cere-
bral and myocardial infarction). Two retrospective studies have
proposed to restrict the use of SR in patients with previous car-
diovascular events of any type (Abrahamsen et al., 2014; Yu et al.,
2015). To date, there are no reports evaluating possible mecha-
nisms for the incidence of cardiovascular events in patients treated
with SR.
Our present results demonstrate that SR induces VSMC to
accumulate extracellularmineral in vitro, and that SR also causes an
additive effect on mineralization when it is co-incubated with AGE.Furthermore we show that the actions of SR on VSMC can be pre-
vented by sulfasalazine and nifedipine, suggesting that in this cell
type SR stimulates the pro-inflammatory pathway of NFkB by
activating the L-type calcium channels. The effect of a structurally
related analogous of nifedipine, lacidipine, on the process of
atherogenesis was demonstrated long time ago. Paoletti et al.,
showed that this calcium antagonist inhibit cholesteryl ester
metabolism in macrophages, and proliferation and migration of
myocytes (Paoletti et al., 1996). In the present study, we show that
the addition of vitamin E þ C to the VSMC cultures prevented the
deleterious effects of both AGE and SR on VSMC number (Fig. 2B),
migration (Fig. 3B) and osteoblastic differentiation (Fig. 6B) prob-
ably counteracting the effects of oxidative stress on these cells
(Fig. 7C). It has been previously demonstrated that vitamin C pro-
vides protection against oxidative stress-induced cellular damage
by scavenging of reactive oxygen species. Vitamin E functions as an
essential lipid soluble antioxidant, scavenging hydro-
peroxylradicals in the lipid milieu. Vitamin E reacts rapidly with
peroxyl radicals to form the corresponding lipid hydroperoxide and
the tocopheryl radical. The tocopheryl radical reacts with vitamin
C; thus, vitamin C is oxidated and vitamin E returns to its reduced
state enabling it to continue scavenging oxidized radicals (vitamin
E recycling). In our study, we show that different doses of ascorbic
acid (vitamin C) can either induce osteoblastic differentiation of
VSMC in vitro and ex vivo (25 mg/mL during 15 days of vitamin C
alone), or reverse the effects of AGE on collagen type 1 production
by VSMC (8.5 mg/mL of vitamin C as an additive for vitamin E
recycling) (Traber and Stevens, 2011).
However it is not clear from our present study if SR enters VSMC
via L-type calcium channels, or simply activates them. In any case,
we show that activation of these channels increases intracellular
ROS (Fig. 7) and thus promotes NFkB, which finally leads to an in-
crease in the proliferative, migratory and pro-osteogenic capacity of
these cells. It has been previously pointed out that oxidative stress
drives the osteoblastic trans-differentiation of VSMC (McCarty and
DiNicolantonio, 2014). Intracellular ROS production can also be
increased by binding of AGE to its cognate receptor RAGE
(McCarthy et al., 2001a): thus it is not unexpected to find that both
AGE and SR promote the osteogenic induction of VSMC, showing an
additive effect when they are co-incubated. Both agents could have
the final result of potentiating activation of the NFkB pathway
Fig. 7. Evaluation of the levels of the reactive oxygen species production induced by AGE and/or SR (A) and the action of nifedipine (B), vitamin E and C (C), Vit D (D) or sulfasalazine
(E). Results are expressed as the mean ± SEM, n ¼ 8. #: p < 0.05 vs. BSA; ##: p < 0.01 vs. BSA; ###: p < 0.001 vs. BSA; **: p < 0.01 vs. AGE; f: p < 0.05 vs. BSA þ SR.
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Our present results with VSMC differ from those previously
reported by our group with osteoblasts in culture (Fernandez et al.,
2013). In our previous work, we found that SR prevented thedeleterious actions of AGE on osteoblasts in culture by activation of
L-type calcium channels and a decrease in the secretion of pro-
inflammatory cytokines. We have yet to elucidate the molecular
reasons for these divergent effects; however, these results highlight
Fig. 8. Proposed mechanism of action of AGE on vascular smooth muscle cells osteoblastic trans-differentiation.
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mulation depends on the cell system under study.
In order to investigate the possible mechanism of action of AGEs
and SR on VSMC, we assessed the signalling to ERK pathway. The
AGE and/or SR-induced number of cells (Fig. 2E) and type 1 collagen
production (Fig. 6D) were totally blocked by PD98058, thus sug-
gestion that ERK phosphorylation could be involved in the osteo-
genic trans-differentiation effects of both, AGE and SR. These results
agree with our previous observations that the anabolic action of
strontium ranelate on osteoblasts is mediated by the activation of
ERK pathway (Fernandez et al., 2013).
In our present study, we have also demonstrated that vitamin D
(cholecalciferol) modulates the osteogenic trans-differentiation of
VSMC in response to AGE and/or SR. Indeed, we found that the
osteogenic differentiation of VSMC was blunted when the cells
exposed to AGE and/or SR were co-incubated with vitamin D.
Moreover, we found that vitamin D exerted an antioxidant effect
and this could be associated with the prevention of Runx2 up-
regulation. VSMC have been previously demonstrated to express
25- and 1a-hydroxylases, suggesting that these cells can metabo-
lize either cholecalciferol or calcidiol (Somjen et al., 2005; Jia et al.,
2016). Additionally, anti-inflammatory properties of 1,25-vitamin D
(calcitriol) have been reported in VSMC (Tukaj et al., 2012). It was
recently demonstrated that calcitriol prevented in vitro VSMCs
mineralization by regulating calcium-sensing receptor expression
(Mary et al., 2015). This evidence points to a significant and pro-
tective role of vitamin D on the vasculature.
Additionally, our results show in an in vitro model a reversion of
SR pro-osteogenic effects on VSMC differentiation by co-treatment
with vitamin D. However, we cannot extrapolate these results to
humans. Further clinical investigations are needed to prove that
this drug association has similar effects in human patients.
In conclusion, we have demonstrated in vitro that AGE and SR
alone or in combination, stimulate L-type calcium channels, induce
an increase in reactive oxygen species, in NFkB signalling pathway
and in ERK activation, promoting an osteogenic shift of VSMC
(Fig. 8). In addition, that these effects of AGE and/or SR can be
prevented by co-incubation with vitamin D.
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